Literature DB >> 19421241

Endocrine and musculoskeletal abnormalities in patients with Down syndrome.

Yousra Hawli1, Mona Nasrallah, Ghada El-Hajj Fuleihan.   

Abstract

Down syndrome has a prevalence of one in 500 to one in 1,000 live births and is the most common cause of mental retardation. Most patients are treated in childhood and adolescence for mental or growth retardation. Studies that evaluate bone mass in Down syndrome are limited, and many are small case series in pediatric and adult populations who live either in the community or in residential institutions. Several environmental and hormonal factors contribute to low bone mineral density in such patients. Muscle hypotonia, low amounts of physical activity, poor calcium and vitamin D intakes, hypogonadism, growth retardation and thyroid dysfunction contribute to substantial impairments in skeletal maturation and bone-mass accrual that predispose these patients to fragility fractures. Here, we review indications and limitations of bone-mass measurements in children, summarize the endocrine and skeletal abnormalities in patients presenting with Down syndrome, and review studies that investigate therapeutic strategies for such patients.

Entities:  

Mesh:

Year:  2009        PMID: 19421241     DOI: 10.1038/nrendo.2009.80

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  64 in total

1.  Bone mineral mass in males and females with and without Down syndrome.

Authors:  Fatima Baptista; Ana Varela; Luis B Sardinha
Journal:  Osteoporos Int       Date:  2004-09-09       Impact factor: 4.507

2.  Fertility in a male with trisomy 21.

Authors:  M Bobrow; T Barby; A Hajianpour; D Maxwell; S C Yau
Journal:  J Med Genet       Date:  1992-02       Impact factor: 6.318

Review 3.  Current dilemmas in Down syndrome clinical care: celiac disease, thyroid disorders, and atlanto-axial instability.

Authors:  William I Cohen
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-08-15       Impact factor: 3.908

4.  Bone mass, gonadal function and biochemical assessment in young men with trisomy 21.

Authors:  Athanasios Sakadamis; Nickoletta Angelopoulou; Chrysoula Matziari; Vasilios Papameletiou; Vasilios Souftas
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2002-01-10       Impact factor: 2.435

5.  Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.

Authors:  M C Chapuy; R Pamphile; E Paris; C Kempf; M Schlichting; S Arnaud; P Garnero; P J Meunier
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

6.  Fracture epidemiology and control in a developmental center.

Authors:  G S Lohiya; F M Crinella; L Tan-Figueroa; S Caires; S Lohiya
Journal:  West J Med       Date:  1999-04

7.  Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation.

Authors:  S Castells; I Beaulieu; C Torrado; K E Wisniewski; S Zarny; M C Gelato
Journal:  J Intellect Disabil Res       Date:  1996-12

8.  Age-related patterns of thyroid-stimulating hormone response to thyrotropin-releasing hormone stimulation in Down syndrome.

Authors:  T Sharav; H Landau; Z Zadik; T R Einarson
Journal:  Am J Dis Child       Date:  1991-02

9.  Can BMD assessed by DXA at age 8 predict fracture risk in boys and girls during puberty?: an eight-year prospective study.

Authors:  Jennifer Flynn; Stella Foley; Graeme Jones
Journal:  J Bone Miner Res       Date:  2007-09       Impact factor: 6.741

Review 10.  Prenatal and childhood influences on osteoporosis.

Authors:  M K Javaid; Cyrus Cooper
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2002-06       Impact factor: 4.690

View more
  28 in total

1.  Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.

Authors:  Joshua D Blazek; Anna Gaddy; Rachel Meyer; Randall J Roper; Jiliang Li
Journal:  Bone       Date:  2010-09-24       Impact factor: 4.398

2.  Bone mineral density in adults with Down syndrome.

Authors:  A Carfì; R Liperoti; D Fusco; S Giovannini; V Brandi; D L Vetrano; E Meloni; D Mascia; E R Villani; E Manes Gravina; R Bernabei; G Onder
Journal:  Osteoporos Int       Date:  2017-07-06       Impact factor: 4.507

Review 3.  Aneuploidy and skeletal health.

Authors:  Archana Kamalakar; John R Harris; Kent D McKelvey; Larry J Suva
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

4.  Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

Authors:  Matthew Tamplen; Tristan Fowler; Jeffery Markey; P Daniel Knott; Larry J Suva; Tamara Alliston
Journal:  Head Neck       Date:  2018-03-09       Impact factor: 3.147

Review 5.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

6.  Diverging results of areal and volumetric bone mineral density in Down syndrome.

Authors:  M García-Hoyos; M T García-Unzueta; D de Luis; C Valero; J A Riancho
Journal:  Osteoporos Int       Date:  2016-11-12       Impact factor: 4.507

Review 7.  Neurological phenotypes for Down syndrome across the life span.

Authors:  Ira T Lott
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

8.  Low bone turnover and low bone density in a cohort of adults with Down syndrome.

Authors:  K D McKelvey; T W Fowler; N S Akel; J A Kelsay; D Gaddy; G R Wenger; L J Suva
Journal:  Osteoporos Int       Date:  2012-08-18       Impact factor: 4.507

9.  Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.

Authors:  Irushi Abeysekera; Jared Thomas; Taxiarchis M Georgiadis; Alycia G Berman; Max A Hammond; Karl J Dria; Joseph M Wallace; Randall J Roper
Journal:  Mol Nutr Food Res       Date:  2016-02-11       Impact factor: 5.914

Review 10.  Skeletal dynamics of Down syndrome: A developing perspective.

Authors:  Jonathan M LaCombe; Randall J Roper
Journal:  Bone       Date:  2019-12-27       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.